Bénédicte Lebrun-Vignes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/802308/publications.pdf

Version: 2024-02-01

60 papers 5,354 citations

218677 26 h-index 57 g-index

62 all docs 62 docs citations

62 times ranked 5732 citing authors

#	Article	IF	CITATIONS
1	Systematic analysis of drug-associated myocarditis reported in the World Health Organization pharmacovigilance database. Nature Communications, 2022, 13, 25.	12.8	44
2	Biases associated with epidermal necrolysis reporting in pharmacovigilance: An exploratory analysis using World Health Organization VigiBase. Pharmacoepidemiology and Drug Safety, 2022, 31, 434-441.	1.9	2
3	Anti-MOG associated disease with intracranial hypertension after COVID-19 vaccination. Journal of Neurology, 2022, 269, 5647-5650.	3.6	5
4	Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database. Scientific Reports, 2022, 12, 7140.	3.3	45
5	Sweet-like syndrome and multiple COVID arm syndrome following COVID-19 vaccines:  specific' patterns in a series of 192 patients. British Journal of Dermatology, 2022, 187, 615-617.	1.5	6
6	Androgenic effects on ventricular repolarization: A translational study from the international pharmacovigilance database to iPSC-cardiomyocytes. Annales D'Endocrinologie, 2021, 82, 132-133.	1.4	2
7	A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor–Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention. Cancer Discovery, 2021, 11, 614-625.	9.4	145
8	Characterization of drug-induced cutaneous lupus: Analysis of 1994 cases using the WHO pharmacovigilance database. Autoimmunity Reviews, 2021, 20, 102705.	5.8	7
9	Atrial fibrillation in patients treated with intravenous zoledronic or pamidronic acid: a pharmacoepidemiological study. European Journal of Endocrinology, 2021, 184, 437-444.	3.7	6
10	Characteristics of insulinopenic and non insulinopenic diabetes related to immune checkpoint inhibitors: A French pharmacovigilance study. Therapie, 2021, 76, 695-703.	1.0	5
11	Relapsing generalized bullous fixed drug eruption: A severe and avoidable cutaneous drug reaction. Three case reports. Therapie, 2021, , .	1.0	4
12	Sipuleucel†associated inflammatory cardiomyopathy: a case report and observations from a large pharmacovigilance database. ESC Heart Failure, 2021, 8, 3360-3368.	3.1	3
13	Transplant rejections associated with immune checkpoint inhibitors: A pharmacovigilance study and systematic literature review. European Journal of Cancer, 2021, 148, 36-47.	2.8	42
14	Towards a better understanding of adult idiopathic epidermal necrolysis: a retrospective study of 19 cases. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1569-1576.	2.4	4
15	Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study. European Heart Journal, 2021, 42, 3915-3928.	2.2	38
16	Incidence of and mortality from epidermal necrolysis (Stevens–Johnson syndrome/toxic epidermal) Tj ETQq0 0 0 Dermatology, 2020, 182, 618-624.	0 rgBT /Ov 1.5	verlock 10 Tf : 29
17	Heart failure and atrial tachyarrhythmia on abiraterone: A pharmacovigilance study. Archives of Cardiovascular Diseases, 2020, 113, 9-21.	1.6	27
18	Characterization of auto-immune hepatitis associated with the use of anti-TNFα agents: An analysis of 389 cases in VigiBase. Autoimmunity Reviews, 2020, 19, 102460.	5.8	21

#	Article	IF	CITATIONS
19	Answer to Tahri et al. «ÂRetinoid Hyperostosis, an overlooked cause of atypical sacroiliac pain in young patients: A pharmacovigilance survey». Joint Bone Spine 2020. doi: 10.1016/j.jbspin.2020.06.023. Joint Bone Spine, 2020, 87, 523-524.	1.6	0
20	Uses of pharmacovigilance databases: An overview. Therapie, 2020, 75, 591-598.	1.0	92
21	Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase. Circulation, 2020, 142, 2443-2455.	1.6	121
22	Cardiotoxicity Associated with Gemcitabine: Literature Review and a Pharmacovigilance Study. Pharmaceuticals, 2020, 13, 325.	3.8	23
23	Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis. Oncologist, 2020, 25, 696-701.	3.7	73
24	Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities. Autoimmunity Reviews, 2020, 19, 102586.	5.8	80
25	Increased reporting of fatal pneumonitis associated with immune checkpoint inhibitors: a WHO pharmacovigilance database analysis. European Respiratory Journal, 2020, 55, 2000038.	6.7	19
26	Solid organ transplant rejection associated with immune-checkpoint inhibitors. Annals of Oncology, 2020, 31, 543-544.	1.2	11
27	Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHO's pharmacovigilance database. Journal of Autoimmunity, 2020, 111, 102454.	6.5	11
28	Graft Versus Host Disease Associated with Immune Checkpoint Inhibitors: A Pharmacovigilance Study and Systematic Literature Review. Frontiers in Pharmacology, 2020, 11, 619649.	3.5	5
29	Androgenic Effects on Ventricular Repolarization. Circulation, 2019, 140, 1070-1080.	1.6	67
30	Drugâ€induced aseptic meningitis: 329 cases from the French pharmacovigilance database analysis. British Journal of Clinical Pharmacology, 2019, 85, 2540-2546.	2.4	17
31	A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis. Nature Medicine, 2019, 25, 1243-1250.	30.7	133
32	Clinical characterization of men with long QT syndrome and torsades de pointes associated with hypogonadism: A review and pharmacovigilance study. Archives of Cardiovascular Diseases, 2019, 112, 699-712.	1.6	18
33	Increased reporting of fatal hepatitis associated with immune checkpoint inhibitors. European Journal of Cancer, 2019, 123, 112-115.	2.8	17
34	Cardiovascular Toxicities AssociatedÂWith Ibrutinib. Journal of the American College of Cardiology, 2019, 74, 1667-1678.	2.8	169
35	Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database. Annals of the Rheumatic Diseases, 2019, 78, 504-508.	0.9	54
36	Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. , 2019, 7, 134.		237

#	Article	IF	Citations
37	Hematologic Complications of Immune Checkpoint Inhibitors. Oncologist, 2019, 24, 584-588.	3.7	103
38	Lookalike and soundalike drugs: a potential cause of cutaneous adverse reactions to drugs. British Journal of Dermatology, 2019, 181, 626-627.	1.5	2
39	lmmune checkpoint inhibitor–associated hypophysitis—World Health Organisation VigiBase report analysis. European Journal of Cancer, 2019, 113, 10-13.	2.8	23
40	Valaciclovir: a culprit drug for drug reaction with eosinophilia and systemic symptoms not to be neglected. Three cases. British Journal of Dermatology, 2019, 180, 666-667.	1.5	6
41	Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: Proportion and determinants of underreporting to pharmacovigilance. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1344-1346.	3.8	0
42	Characterizing drug-induced capillary leak syndromes using the World Health Organization VigiBase. Journal of Allergy and Clinical Immunology, 2019, 143, 433-436.	2.9	32
43	Drugâ€induced linear immunoglobulin A bullous dermatosis: A French retrospective pharmacovigilance study of 69 cases. British Journal of Clinical Pharmacology, 2019, 85, 570-579.	2.4	41
44	Checkpoint inhibitor-associated immune arthritis. Annals of the Rheumatic Diseases, 2019, 78, e68-e68.	0.9	27
45	Severe cutaneous adverse reactions due to inappropriate medication use. British Journal of Dermatology, 2018, 179, 329-336.	1.5	17
46	Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet, The, 2018, 391, 933.	13.7	618
47	Is acetaminophen associated with a risk of Stevens–Johnson syndrome and toxic epidermal necrolysis? Analysis of the French Pharmacovigilance Database. British Journal of Clinical Pharmacology, 2018, 84, 331-338.	2.4	25
48	Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncology, The, 2018, 19, 1579-1589.	10.7	742
49	Immune Checkpoint Inhibitor–Associated Myositis. Circulation, 2018, 138, 743-745.	1.6	139
50	Increased Reporting of Immune Checkpoint Inhibitor–Associated Diabetes. Diabetes Care, 2018, 41, e150-e151.	8.6	82
51	Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors. JAMA Oncology, 2018, 4, 1721.	7.1	1,625
52	Reporting of immune checkpoint inhibitor-associated myocarditis – Authors' reply. Lancet, The, 2018, 392, 384-385.	13.7	7
53	Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors. Heart, 2018, 104, 1859-1863.	2.9	37
54	Tratamientos tópicos del acné y de la rosácea. EMC - DermatologÃa, 2018, 52, 1-10.	0.1	0

#	Article	IF	CITATIONS
55	Reporting of harm and safety results in randomized controlled trials published in 5 dermatology journals. Journal of the American Academy of Dermatology, 2017, 77, 98-104.e1.	1.2	15
56	Immediate hypersensitivity reaction to pegylated liposomal doxorubicin: management and outcome in four patients. European Journal of Dermatology, 2017, 27, 271-274.	0.6	11
57	Linear IgA bullous dermatosis: comparison between the drug-induced and spontaneous forms. British Journal of Dermatology, 2013, 169, 1041-1048.	1.5	99
58	Safety of Topical Corticosteroid Use During Pregnancy. Archives of Dermatology, 2012, 148, 525.	1.4	3
59	Comparative analysis of adverse drug reactions to tetracyclines: results of a French national survey and review of the literature. British Journal of Dermatology, 2012, 166, 1333-1341.	1.5	52
60	A meta-analysis to assess the efficacy of oral antiviral treatment to prevent genital herpes outbreaks. Journal of the American Academy of Dermatology, 2007, 57, 238-246.	1.2	56